Latigo Biotherapeutics Names Todd N. Smith CEO; Farzan to Advise Through 2027
Todd N. Smith succeeds Nima Farzan as CEO. Farzan will remain a strategic advisor through 2027.
Todd N. Smith succeeds Nima Farzan as CEO. Farzan will remain a strategic advisor through 2027.